Search This Blog

Wednesday, August 12, 2026

'AP: Amid Flesh-Eating Bacteria Deaths, Health Officials Urge Caution for Beachgoers'

 Health officials in Louisiana are urging beachgoers to take precautions during a summertime surge in infections from a flesh-eating bacteria found in coastal waters.

Louisiana has confirmed nine cases of Vibrio vulnificus infections this year, the state's health department said last week in a news release. All were hospitalized, and five died. During the same period over the previous decade, Louisiana reported an average of seven cases and one death.

"Seek medical care immediately if a wound exposed to brackish or salt water becomes red, swollen, painful, warm or discolored," officials said in the release. "Tell the healthcare provider about the water exposure."

The Gulf Is an Ideal Environment

Vibrio bacteria thrive in seawater and in the brackish mix of fresh and saltwater found in estuaries and lagoons. Most infections are reported from May to October, and most happen in states along the Gulf Coast. Doctors say the Gulf is an ideal environment with the right amounts of salt and heat to let this organism proliferate.

The mostly deadly type is Vibrio vulnificus, according to the CDC. As many as one in five of those infections are fatal, a much higher rate than other types of Vibrio bacteria.

Florida, which tends to have more infections than other states, has reported 14 Vibrio vulnificus cases and two deaths so far this year, compared with 33 cases and five deaths for all of last year. Records show more cases in years when Florida is hit by tropical storms and hurricanes.

Bacteria Enters Through Breaks in the Skin

Some people become infected by eating raw or undercooked shellfish -- particularly oysters. But a large percentage fall ill when the person is in ocean or brackish water and the bacteria enter the body through small breaks in the skin.

Doctors say severe cases are seen more often in elderly patients, people with weakened immune systems, and those with liver disease, diabetes, and certain chronic illnesses.

Scientists say climate change is helping the germs proliferate and spread northward. A 2023 study found that the northernmost case has been shifting by about 30 miles each year, and that cases overall have been rising.

Beachgoers Can Protect Themselves

Vibrio vulnificus can enter the body through unhealed cuts and scrapes, recent piercings and tattoos, and recent surgical incisions. People should immediately wash cuts and scrapes thoroughly with soap and clean running water after coming in contact with coastal waters or raw seafood, the CDC said. They should see a doctor if they start to develop symptoms such as fever, chills, and hot red areas on the skin that start to turn dark and blister.

Oysters are a particular risk, and there is no way to tell if an oyster is contaminated just by looking at it. People should wash hands with soap and water after handling raw shellfish and wear protective gloves if they have a weakened immune system and are at a higher risk of infection.

Health officials also offer cooking instructions for clams, mussels, and other shellfish. They recommend throwing away any with open shells before boiling or steaming.

https://www.medpagetoday.com/publichealthpolicy/publichealth/122543

Most Older Diabetics Don't Get Recommended Medication Tweaks

 

  • Guidelines recommend individualizing HbA1c goals to health status in older adults with type 2 diabetes.
  • A review of electronic health records found that most older adults with type 2 diabetes outside target HbA1c goals didn't receive medication adjustments in the right direction.
  • Only 17% of below-goal patients had their regimen deintensified, while 33% of above-goal patients had their treatment intensified.

Most older adults with type 2 diabetes whose HbA1c level was outside the American Diabetes Association (ADA)-recommended target did not have their medications adjusted, a review of electronic health records indicated.

Among nearly 90,000 patients ages 65 and older, only 16.9% of those with an HbA1c below guideline goals had their regimen deintensified. Meanwhile, only 32.8% of patients whose HbA1c was above goal had their treatment intensified, reported researchers led by Phuc Le, PhD, MPH, of the Cleveland Clinic, in JAMA Internal Medicine.

"There are opportunities to improve treatment alignment at both ends of the glycemic spectrum," with the goal of achieving the right treatment intensity for each individual patient, Le told MedPage Today.

"Some patients in poor health with HbA1c substantially below goal who may be most vulnerable to the harms of overly intensive glycemic control continued to have treatment intensified," she said. "At the same time, some patients in good health with HbA1c above goal who could benefit from intensive control did not receive treatment intensification."

ADA guidelines recommend individualizing HbA1c goals based on health status. Patients with significant cognitive or functional limitations, frailty, or severe comorbidities should follow less stringent targets to avoid hypoglycemia. In contrast, healthier patients with longer life expectancies may follow a more intensive regimen with goals similar to younger adults.

"Clinicians should consider the patient's overall health, comorbidities, functional status, life expectancy, and treatment preferences when setting a glycemic goal, and then periodically reassess whether the medication regimen remains appropriate for that goal," Le advised.

For the analysis, researchers evaluated electronic health record data from 2019 through 2023. HbA1c was defined as "at goal" if it was between 0 and 1.5 percentage points below the ADA's specified targets, stratified by health status as follows:

  • Poor health (one or more terminal conditions): Below 9%
  • Intermediate health (three or more chronic conditions): Below 8%
  • Good health (neither condition): Below 7.5%

Outside of the at-goal range, HbA1c levels were categorized as either below or above goal. Intensification and deintensification were defined as an increase or decrease in the number of diabetes drug classes or non-insulin drug dosages within 3 months after versus 3 months before the index HbA1c ​measurement.

Across the study period, 7.9% of patients had good health, 61.6% had intermediate health, and 30.6% had poor health status. Overall, 13.8% of patients had above-goal, 37.8% had at-goal, and 48.4% had below-goal HbA1c​ levels. Average age of the cohort was roughly 71.6 years, and half of the patients were men.

In 2023, those with above-goal HbA1c ​were more likely to experience medication intensification (32.8% vs 16.1%, P<0.001) or deintensification (20.3% vs 16.3%, P<0.001) compared with at-goal patients. Intensification patterns were similar across health statuses, including among healthy older adults.

"This represents a missed opportunity to improve glycemic control in otherwise healthy older adults, placing them at risk for long-term complications, such as retinopathy, nephropathy, and cardiovascular disease," the authors wrote.

Conversely, those with below-goal HbA1c ​had a similar rate of deintensification compared with at-goal patients (16.9% vs 16.3%, P=0.338) and a lower rate of intensification (7.7% vs 16.1%, P<0.001) compared with at-goal patients.

However, intensification for below-goal levels occurred most frequently in patients with poor health. The researchers called this finding concerning, "because intensive glycemic control in frail or medically complex older adults is associated with increased risks of hypoglycemia and other adverse outcomes."

Deintensification should not be viewed as providing less care, Le stressed.

"In some older adults, safely reducing medication burden can be an important part of good diabetes care," she noted. "The goal is to balance the long-term benefits of glycemic control against treatment burden and potential adverse effects, particularly hypoglycemia, in patients with substantial comorbidity or limited life expectancy."

The study could not determine why individual clinicians intensified, deintensified, or maintained treatment, Le acknowledged.

"Therefore, these results should not be interpreted to mean that every HbA1c value outside the guideline range requires a medication change," she said. "Rather, they highlight opportunities for clinicians to make individualized glycemic goals a more explicit part of clinical decision-making."

Next steps should focus on improving adherence to guideline recommendations and leveraging safer medication options, the authors concluded.

Disclosures

Le reported no disclosures. Co-authors reported relationships with the NIH, the Patient-Centered Outcomes Research Institute, Bayer, and Blue Cross Blue Shield Association.

'GLP-1 Telehealth Platforms Rated by U.S. News'

 For the first time ever, U.S. News & World Report has released ratings of telehealth platforms offering GLP-1 weight-loss drugs.

The inaugural ratings evaluated 20 online platforms that offer FDA-approved, brand-name GLP-1 medications, such as semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo).

Overall, 11 of the platforms received top ratings, including Amazon One Medical, Noom, Ro, and WeightWatchers.

Companies that only offer compounded GLP-1 medications -- which are not FDA-approved and may carry greater risks -- were not included in the ratings. However, some telehealth platforms included in the ratings may provide compounded medications, U.S. News noted.

The company pointed to growing demand for GLP-1 medications as the reason for rolling out the new resource, adding that patients have to navigate complicated fee structures, varying levels of physician oversight, and complex insurance processes when trying to find a good telehealth provider.

"As millions of Americans look online to access these treatments, they're facing a crowded, confusing landscape filled with hidden costs and varying levels of clinical care and oversight," Gretel Schueller, managing editor of health at U.S. News, said in a statement. "Our debut ratings were designed to cut through that noise so they can find a trustworthy telehealth provider of GLP-1s."

Schueller noted that a U.S. News survey from earlier this year revealed that 52% of health experts said GLP-1 expansion would be the "single biggest public health trend of 2026."

She added that telehealth platforms should "serve as a tool to support" patient care, rather than being a replacement for in-person care, urging patients to "look for platforms offering real-time interaction with a licensed healthcare provider, and to always keep their primary care physician in the loop to align GLP-1 treatment with their long-term health goals."

Schueller also said in the statement that each telehealth platform caters to specific needs. For instance, Amazon One Medical has dedicated insurance support, Found has thorough medical oversight, Noom has comprehensive lifestyle and nutrition coaching, and Ro has the best customer satisfaction.

She noted 85% of respondents to user feedback surveys rated their experience with their telehealth platform as "very good" or "excellent," and nearly two-thirds lost more than 10% of their body weight. When people "choose a telehealth platform grounded in high clinical standards," Schueller said, using telehealth to get GLP-1s can be "an effective and safe way to lose weight."

To determine the ratings, U.S. News evaluated platforms on a 5-point scale across 6 categories -- including clinical support, health screening processes, transparency, insurance support, supplemental support, and customer satisfaction -- as well as feedback from more than 1,200 active GLP-1 telehealth users.

The 11 top performing GLP-1 telehealth platforms were as follows:

  • Amazon One Medical
  • Found
  • Fridays
  • Ivim Health
  • LifeMD
  • Mochi Health
  • Noom
  • PlushCare
  • Remedy Meds
  • Ro
  • WeightWatchers

'Daiichi, AstraZeneca drug Enhertu wins further approval in China'

 Daiichi Sankyo Co Ltd on Wednesday said Enhertu, which it is developing alongside AstraZeneca PLC, received another approval in China.

Tokyo-based Daiichi said the drug was backed by China's National Medical Products Administration for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.

The approval, which is based on phase 3 trial data results, is for Enhertu plus pertuzumab.

Daiichi said the combination reduced the risk of disease progression or death by 44% compared to taxane, trastuzumab and pertuzumab in patients with HER2 positive metastatic breast cancer who had not received prior chemotherapy or HER2 targeted therapy or had received neoadjuvant or adjuvant HER2 targeted therapy more than six months before the diagnosis of advanced or metastatic disease.

Daiichi shares had closed flat at JPY2,805.00 each on Wednesday in Tokyo, while Cambridge-based AstraZeneca traded 1.5% lower at 11,672.00 pence each on Wednesday afternoon in London.

https://global.morningstar.com/en-gb/news/alliance-news/1786541330570824900/daiichi-astrazeneca-drug-enhertu-wins-further-approval-in-china

Raising Our S&P 500 Earnings & Price Targets Outlook Due To FEMO (Fabulous Earnings Momentum)

 


I. Quarterly Earnings Per Share

What a fabulous Q2-2026 earnings season it has been! So far, 90% of S&P 500 companies have reported. They broadly crushed industry analysts' forecasts for earnings and profit margins, both of which saw a boost from mark-to-market (MTM) gains from Alphabet and Amazon for a second straight quarter. These MTM gains (along with Meta’s little-mentioned gain from a tax reversal) boosted earnings by $5.88 to $75.03 during Q1 and by $14.00 to $97.83 in Q2 (chart).

As a result, S&P 500 EPS rose 19.0% y/y in Q1 and 46.7% y/y in Q2. Without the MTM gains, earnings rose 9.5% and 25.7% during those two quarters (chart)

https://www.yardeniquicktakes.com/raising-our-s-p-500-earnings-price-targets-outlook-due-to-femo-fabulous-earnings-momentum/

'Iran, Pakistan are each other's 'strategic depth,' security chief Rezaei says'

 

Iran and Pakistan are each other's "strategic depth," Iran's Supreme National Security Council Secretary Mohsen Rezaei said during a meeting with Pakistani Interior Minister Mohsin Naqvi, according to Tasnim news agency.

"All leaders of the Islamic Republic of Iran have regarded Pakistan as Iran's strategic depth and Iran as Pakistan's strategic depth," Rezaei said.

He said Iran viewed Pakistan's government, military and people as major partners and welcomed what he described as increased regional engagement by Pakistan's prime minister and army chief.

Rezaei also said President Masoud Pezeshkian placed particular importance on relations with Pakistan and wanted bilateral trade to increase severalfold.

https://www.iranintl.com/en/202608121213

https://nypost.com/2026/08/12/opinion/mamdani-learned-all-the-wrong-lessons-from-idi-amins-third-worldism/